A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia (ET-01)
A Multicenter, Open Label Phase 1 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion Dependent Β-Thalassaemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital of Southern Medical University
-
Guangzhou, Guangdong, China, 510623
- Guangzhou Women and Children's Medical Center
-
Shenzhen, Guangdong, China, 518035
- Shenzhen Children's Hospital
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Institute of Hematology & Blood Diseases Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Subjects and/or legal representative fully understand and voluntarily sign informed consent forms.
- Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol.
- Be not appropriate to receive conventional allogeneic hematopoietic stem cell transplantation.
- Lansky/Karnofsky score ≥ 70%.
- Eligible for hematopoietic stem cell transplantation and conditioning with busulfan as per investigator's judgement.
Other protocol defined inclusion criteria may apply.
Key Exclusion Criteria:
- Subjects with associated α-thalassemia.
- Subjects with any clinically significant acute or uncontrolled infections.
- History of uncontrolled epilepsy or other mental disorders.
- Previous treatment with allogeneic bone marrow transplantation or gene therapy.
Other protocol defined exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ET-01
|
Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequency and severity of collected AEs & SAEs
Time Frame: Within 24 months after ET-01 infusion
|
Within 24 months after ET-01 infusion
|
|
All-cause mortality
Time Frame: From signing of informed consent up to 24 months post-ET-01 infusion
|
From signing of informed consent up to 24 months post-ET-01 infusion
|
|
Incidence of transplant-related mortality
Time Frame: From baseline (pre-transfusion) up to 12 months post-ET-01 infusion
|
From baseline (pre-transfusion) up to 12 months post-ET-01 infusion
|
|
Total lymphocyte count
Time Frame: Within 24 months after ET-01 infusion
|
Within 24 months after ET-01 infusion
|
|
Proportion of subjects with abnormal proliferation of blood cells
Time Frame: Within 24 months after ET-01 infusion
|
Within 24 months after ET-01 infusion
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EDG-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.